Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GYS1 | P13807 | 11/20 | 0.39 |
| ▸ | CFD | P00746 | 4/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | IGF1R | P08069 | 2/20 | 0.35 |
| ▸ | FLT4 | P35916 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.35 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.34 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7314411 | 0.82 | LTB4R (0.49) | GYS1CFDEGFRIGF1RFLT4 | |
| SCHEMBL7314423 | 0.82 | LTB4R (0.49) | GYS1CFDEGFRIGF1RFLT4 | |
| SCHEMBL7309258 | 0.82 | CFD (0.42) | CFDEGFRIGF1RFLT4KDR | |
| SCHEMBL7309274 | 0.82 | CFD (0.42) | CFDEGFRIGF1RFLT4KDR | |
| SCHEMBL7308134 | 0.80 | EGFR (0.47) | EGFRIGF1RFLT4KDRLTB4R | |
| SCHEMBL7309613 | 0.79 | EGFR (0.41) | EGFRIGF1RFLT4KDRLTB4R | |
| SCHEMBL7318098 | 0.79 | EGFR (0.43) | EGFRIGF1RFLT4KDRLTB4R | |
| SCHEMBL7318472 | 0.78 | EGFR (0.44) | EGFRIGF1RFLT4KDRLTB4R | |
| SCHEMBL7317988 | 0.78 | EGFR (0.39) | EGFRIGF1RFLT4KDRLTB4R | |
| SCHEMBL7321372 | 0.78 | KDR (0.39) | EGFRIGF1RFLT4KDRLTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION | 2001-07-12 | — | — | US | claimed |
| WO-2001034146-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | claimed |
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION | 2001-07-12 | — | — | US | disclosed |
| WO-2001034146-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | CTSL, MMP8, SERPINB1 | GYS1 4347/4885CFD 3192/4885EGFR 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.